Sanofi Genzyme News |

Featured Press Releases

June 2, 2019
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
Pivotal Phase 3 ICARIA-MM trial results demonstrated that isatuximab added to pomalidomide and dexamethasone (isatuximab combination therapy) showed statistically significant improvements compared to pomalidomide and dexamethasone (pom-dex) alone in patients with relapsed/refractory multiple myeloma (RRMM)....
May 16, 2019
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that positive updated data for Libtayo® (cemiplimab-rwlc) in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) will be shared at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in...
May 15, 2019
Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019
Sanofi’s oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering against a renewed strategy to address difficult-to-treat and difficult-to-eradicate cancers, including certain types of multiple myeloma, skin cancer, breast...
May 7, 2019
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
The European Commission has approved Dupixent® (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately...

Leadership

Bill Sibold
Executive Vice President and Head of Sanofi Genzyme
Bill joined Sanofi Genzyme in 2011 as Senior Vice President and Head of Multiple Sclerosis, and oversaw the successful launches of its two MS treatments. As Head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology. More...

Tweets

2 days until #WorldSickleCellDay. This year we “Shine the Light on Sickle Cell” to raise awareness about this globa… https://t.co/2QFV60pEJA-37 min 26 sec ago

Our #ASMD team enjoyed meeting with the Board of the @inpda_org at the 6th Biennial Face to Face meeting of the Int… https://t.co/FYfgR7dvJ2-4 hours 7 min ago

We are committed to contributing meaningful solutions for patients battling rare blood disorders, rare genetic cond… https://t.co/yiDzEQUxTV-1 day 5 hours ago

#DYK #Gaucher disease can be easily diagnosed or ruled out with a simple blood test? To learn how you can help avoi… https://t.co/hna3NNHk43-1 day 8 hours ago

We are committed to contributing meaningful solutions for patients battling rare blood disorders, rare genetic cond… https://t.co/uw02qKuRVW-1 day 10 hours ago

Search Newsroom

Featured Press Releases

Featured Videos

Leadership

Media Resources

Tweets

Social Media